EREmanuele de Rinaldis

Emanuele de Rinaldis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emanuele de Rinaldis has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single-cell multi-ancestry regulatory map of systemic lupus erythematosus

    by Haerin Jang, Catherine Sutherland, Wanseon Lee, Niek de Klein, Tarran S. Rupall, Bess L. Chau, Eliora Violain Buyamin, Norzawani Buang, Magdalena West, Chris Wincup, et al.

    Integrating genomic and single-cell transcriptomic profiles from patient cohorts can uncover regulatory effects underlying genetic associations with disease. Here we present SLEmap, a multi-ancestry single-cell expression quantitative trait locus (sc-eQTL) map generated from peripheral blood mononuclear cells from 281 patients with systemic lupus erythematosus (SLE). We identified 18,608 independent eQTLs in 5,656 genes, of which 149 signals in 66 genes colocalized with SLE GWAS loci. Nearly half of these colocalizations were detected exclusively through cell type-level analyses, highlighting the importance of cellular context for interpreting disease-associated genetic variation. Multi-ancestry data identified regulatory signals robust across diverse ancestral backgrounds and improved signal resolution. Most colocalizations were undetectable in sc-eQTLs from a healthy cohort (OneK1K), with novel SLE colocalizations highlighting disease-relevant regulatory mechanisms across distinct cell types, including the NF-κB pathway. These findings demonstrate the value of disease-specific, multi-ancestry single-cell regulatory maps for resolving the genes and cellular mechanisms underlying disease-associated genetic variation.

  • Open Access

    Immune disease dialogue of chemokine-based cell communications as revealed by single-cell RNA sequencing meta-analysis

    by Mouly F. Rahman, Andre H. Kurlovs, Munender Vodnala, Elamaran Meibalan, Terry K. Means, Nima Nouri, Emanuele de Rinaldis, Virginia Savova

    Immune-mediated diseases are characterized by aberrant immune responses, posing significant challenges to global health. In both inflammatory and autoimmune diseases, dysregulated immune reactions mediated by tissue-residing immune and non-immune cells precipitate chronic inflammation and tissue damage that is amplified by peripheral immune cell extravasation into the tissue. Chemokine receptors are pivotal in orchestrating immune cell migration, yet deciphering the signaling code across cell types, diseases and tissues remains an open challenge. To delineate disease-specific cell-cell communications involved in immune cell migration, we conducted a meta-analysis of publicly available single-cell RNA sequencing (scRNA-seq) data across diverse immune diseases and tissues. Our comprehensive analysis spanned multiple immune disorders affecting major organs: atopic dermatitis and psoriasis (skin), chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (lung), ulcerative colitis (colon), IgA nephropathy and lupus nephritis (kidney). By interrogating ligand-receptor (L-R) interactions, alterations in cell proportions, and differential gene expression, we unveiled intricate disease- specific and common immune cell chemoattraction and extravasation patterns. Our findings delineate disease-specific L-R networks and shed light on shared immune responses across tissues and diseases. Insights gleaned from this analysis hold promise for the development of targeted therapeutics aimed at modulating immune cell migration to mitigate inflammation and tissue damage. This nuanced understanding of immune cell dynamics at the single-cell resolution opens avenues for precision medicine in immune disease management.


  • Open Access

    Estimating the impact of single-cell RNA sequencing of human tissues on drug target validation

    by Emma Dann, Erin Teeple, Rasa Elmentaite, Kerstin B Meyer, Giorgio Gaglia, Frank Nestle, Virginia Savova, Emanuele de Rinaldis, Sarah A Teichmann

    Whilst the use of single-cell RNA sequencing (scRNA-seq) to understand target biology is well established, its predictive role in increasing the clinical success of therapeutic targets remains underexplored. Inspired by previous work on an association between genetic evidence and clinical success, we used retrospective analysis of known drug target genes to identify potential predictors of target clinical success from scRNA-seq data. We investigated whether successful drug targets are associated with cell type specific expression in a disease-relevant tissue (cell type specificity), and with cell type specific over-expression in disease patients compared to healthy controls (disease cell specificity). Analysing scRNA-seq data across diseases and tissues, we found that both cell type and disease cell specificity are features enriched in targets entering clinical development, and that cell type specificity in the disease-relevant tissue is robustly predictive of target progression from Phase I to II. While scRNA-seq analysis identifies a larger and complementary target space to that of direct genetic evidence, its association with specificity and drug approval appears less clear. We discuss how further expansion and harmonization of single-cell datasets, more sophisticated integration of this data in target discovery, and improved methods for tracking clinical trial outcomes could enhance our ability to leverage scRNA-seq insights in drug development in future.


  • Vitiligo Skin T Cells Are Prone to Produce Type 1 and Type 2 Cytokines to Induce Melanocyte Dysfunction and Epidermal Inflammatory Response Through Jak Signaling

    by Christina Martins, Laure Migayron, Claire Drullion, Clément Jacquemin, Fabienne Lucchese, Jérôme Rambert, Ribal Merhi, Pauline Michon, Alain Taieb, Hamid-Reza Rezvani, et al.


  • Open Access

    Publisher Correction: An optimized workflow for single-cell transcriptomics and repertoire profiling of purified lymphocytes from clinical samples

    by Richa Hanamsagar, Timothy Reizis, Mathew Chamberlain, Robert Marcus, Frank O. Nestle, Emanuele de Rinaldis, Virginia Savova

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.


  • Open Access

    An optimized workflow for single-cell transcriptomics and repertoire profiling of purified lymphocytes from clinical samples

    by Richa Hanamsagar, Timothy Reizis, Mathew Chamberlain, Robert Marcus, Frank O. Nestle, Emanuele de Rinaldis, Virginia Savova

    Establishing clinically relevant single-cell (SC) transcriptomic workflows from cryopreserved tissue is essential to move this emerging immune monitoring technology from the bench to the bedside. Improper sample preparation leads to detrimental cascades, resulting in loss of precious time, money and finally compromised data. There is an urgent need to establish protocols specifically designed to overcome the inevitable variations in sample quality resulting from uncontrollable factors in a clinical setting. Here, we explore sample preparation techniques relevant to a range of clinically relevant scenarios, where SC gene expression and repertoire analysis are applied to a cryopreserved sample derived from a small amount of blood, with unknown or partially known preservation history. We compare a total of ten cell-counting, viability-improvement, and lymphocyte-enrichment methods to highlight a number of unexpected findings. Trypan blue-based automated counters, typically recommended for single-cell sample quantitation, consistently overestimate viability. Advanced sample clean-up procedures significantly impact total cell yield, while only modestly increasing viability. Finally, while pre-enrichment of B cells from whole peripheral blood mononuclear cells (PBMCs) results in the most reliable BCR repertoire data, comparable T-cell enrichment strategies distort the ratio of CD4+ and CD8+ cells. Furthermore, we provide high-resolution analysis of gene expression and clonotype repertoire of different B cell subtypes. Together these observations provide both qualitative and quantitative sample preparation guidelines that increase the chances of obtaining high-quality single-cell transcriptomic and repertoire data from human PBMCs in a variety of clinical settings.

  • Open Access

    Interplay between the human gut microbiome and host metabolism

    by Alessia Visconti, Caroline I. Le Roy, Fabio Rosa, Niccolo' Rossi, Tiphaine C. Martin, Robert P. Mohney, Weizhong Li, Emanuele de Rinaldis, Jordana T. Bell, J. Craig Venter, et al.

    The human gut is inhabited by a complex and metabolically active microbial ecosystem regulating host health. While many studies have focused on the effect of individual microbial taxa, the metabolic potential of the entire gut microbial ecosystem has been largely under-explored. We characterised the gut microbiome of 1,004 twins via whole shotgun metagenomic sequencing (average 39M reads per sample). We observed greater similarity, across unrelated individuals, for functional metabolic pathways (82%) than for taxonomic composition (43%). We conducted a microbiota-wide association study linking both taxonomic information and microbial metabolic pathways with 673 blood and 713 faecal metabolites (Metabolon, Inc.). Metabolic pathways associated with 34% of blood and 95% of faecal metabolites, with over 18,000 significant associations, while species-level results identified less than 3,000 associations, suggesting that coordinated action of multiple taxa is required to affect the metabolome. Finally, we estimated that the microbiome mediated a crosstalk between 71% of faecal and 15% of blood metabolites, highlighting six key species (unclassified Subdoligranulum spp., Faecalibacterium prausnitzii, Roseburia inulinivorans, Methanobrevibacter smithii, Eubacterium rectale, and Akkermansia muciniphila). Because of the large inter-person variability in microbiome composition, our results underline the importance of studying gut microbial metabolic pathways rather than focusing purely on taxonomy to find therapeutic and diagnostic targets.